Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1937 1
1950 1
1951 1
1954 1
1955 1
1958 2
1959 4
1960 2
1961 2
1962 2
1963 7
1964 11
1965 9
1966 5
1967 7
1968 7
1969 14
1970 5
1971 9
1972 14
1973 8
1974 23
1975 27
1976 16
1977 12
1978 11
1979 7
1980 9
1981 9
1982 7
1983 13
1984 12
1985 23
1986 21
1987 18
1988 28
1989 19
1990 19
1991 23
1992 22
1993 15
1994 21
1995 18
1996 20
1997 20
1998 19
1999 12
2000 25
2001 24
2002 30
2003 29
2004 27
2005 36
2006 48
2007 52
2008 41
2009 47
2010 45
2011 39
2012 50
2013 49
2014 52
2015 60
2016 74
2017 65
2018 74
2019 78
2020 86
2021 94
2022 63
2023 75
2024 24

Text availability

Article attribute

Article type

Publication date

Search Results

1,714 results

Results by year

Filters applied: . Clear all
Page 1
Alpelisib for PIK3CA-Mutated, Hormone Receptor-Positive Advanced Breast Cancer.
André F, Ciruelos E, Rubovszky G, Campone M, Loibl S, Rugo HS, Iwata H, Conte P, Mayer IA, Kaufman B, Yamashita T, Lu YS, Inoue K, Takahashi M, Pápai Z, Longin AS, Mills D, Wilke C, Hirawat S, Juric D; SOLAR-1 Study Group. André F, et al. Among authors: mills d. N Engl J Med. 2019 May 16;380(20):1929-1940. doi: 10.1056/NEJMoa1813904. N Engl J Med. 2019. PMID: 31091374 Clinical Trial.
Alpelisib plus fulvestrant for PIK3CA-mutated, hormone receptor-positive, human epidermal growth factor receptor-2-negative advanced breast cancer: final overall survival results from SOLAR-1.
André F, Ciruelos EM, Juric D, Loibl S, Campone M, Mayer IA, Rubovszky G, Yamashita T, Kaufman B, Lu YS, Inoue K, Pápai Z, Takahashi M, Ghaznawi F, Mills D, Kaper M, Miller M, Conte PF, Iwata H, Rugo HS. André F, et al. Among authors: mills d. Ann Oncol. 2021 Feb;32(2):208-217. doi: 10.1016/j.annonc.2020.11.011. Epub 2020 Nov 25. Ann Oncol. 2021. PMID: 33246021 Free article. Clinical Trial.
Prevention of cisplatin-induced ototoxicity in children and adolescents with cancer: a clinical practice guideline.
Freyer DR, Brock PR, Chang KW, Dupuis LL, Epelman S, Knight K, Mills D, Phillips R, Potter E, Risby D, Simpkin P, Sullivan M, Cabral S, Robinson PD, Sung L. Freyer DR, et al. Among authors: mills d. Lancet Child Adolesc Health. 2020 Feb;4(2):141-150. doi: 10.1016/S2352-4642(19)30336-0. Epub 2019 Dec 19. Lancet Child Adolesc Health. 2020. PMID: 31866182 Free PMC article. Review.
Pilot study of probiotic/colostrum supplementation on gut function in children with autism and gastrointestinal symptoms.
Sanctuary MR, Kain JN, Chen SY, Kalanetra K, Lemay DG, Rose DR, Yang HT, Tancredi DJ, German JB, Slupsky CM, Ashwood P, Mills DA, Smilowitz JT, Angkustsiri K. Sanctuary MR, et al. Among authors: mills da. PLoS One. 2019 Jan 9;14(1):e0210064. doi: 10.1371/journal.pone.0210064. eCollection 2019. PLoS One. 2019. PMID: 30625189 Free PMC article. Clinical Trial.
Apixaban for Prevention of Thromboembolism in Pediatric Heart Disease.
Payne RM, Burns KM, Glatz AC, Male C, Donti A, Brandão LR, Balling G, VanderPluym CJ, Bu'Lock F, Kochilas LK, Stiller B, Cnota JF 2nd, Rahkonen O, Khan A, Adorisio R, Stoica S, May L, Burns JC, Saraiva JFK, McHugh KE, Kim JS, Rubio A, Chía-Vazquez NG, Meador MR, Dyme JL, Reedy AM, Ajavon-Hartmann T, Jarugula P, Carlson-Taneja LE, Mills D, Wheaton O, Monagle P. Payne RM, et al. Among authors: mills d. J Am Coll Cardiol. 2023 Dec 12;82(24):2296-2309. doi: 10.1016/j.jacc.2023.10.010. J Am Coll Cardiol. 2023. PMID: 38057072 Clinical Trial.
I: INTRODUCTION.
Floccia C, Sambrook TD, Delle Luche C, Kwok R, Goslin J, White L, Cattani A, Sullivan E, Abbot-Smith K, Krott A, Mills D, Rowland C, Gervain J, Plunkett K. Floccia C, et al. Among authors: mills d. Monogr Soc Res Child Dev. 2018 Mar;83(1):7-29. doi: 10.1111/mono.12348. Monogr Soc Res Child Dev. 2018. PMID: 29468696
Prescription audit.
Smith R, Loh M, Mills D. Smith R, et al. Among authors: mills d. Br Dent J. 2021 Feb;230(4):189. doi: 10.1038/s41415-021-2760-2. Br Dent J. 2021. PMID: 33637908 Free PMC article. No abstract available.
Indole-3-lactic acid associated with Bifidobacterium-dominated microbiota significantly decreases inflammation in intestinal epithelial cells.
Ehrlich AM, Pacheco AR, Henrick BM, Taft D, Xu G, Huda MN, Mishchuk D, Goodson ML, Slupsky C, Barile D, Lebrilla CB, Stephensen CB, Mills DA, Raybould HE. Ehrlich AM, et al. Among authors: mills da. BMC Microbiol. 2020 Nov 23;20(1):357. doi: 10.1186/s12866-020-02023-y. BMC Microbiol. 2020. PMID: 33225894 Free PMC article.
Time course and management of key adverse events during the randomized phase III SOLAR-1 study of PI3K inhibitor alpelisib plus fulvestrant in patients with HR-positive advanced breast cancer.
Rugo HS, André F, Yamashita T, Cerda H, Toledano I, Stemmer SM, Jurado JC, Juric D, Mayer I, Ciruelos EM, Iwata H, Conte P, Campone M, Wilke C, Mills D, Lteif A, Miller M, Gaudenzi F, Loibl S. Rugo HS, et al. Among authors: mills d. Ann Oncol. 2020 Aug;31(8):1001-1010. doi: 10.1016/j.annonc.2020.05.001. Epub 2020 May 13. Ann Oncol. 2020. PMID: 32416251 Free article. Clinical Trial.
1,714 results